Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

AstraZeneca’s blood cancer drug meets main goal in late-stage trial

AstraZeneca Plc’s blood cancer drug Calquence met the main goal of a final-stage study.

Read More »

Takeda scraps late-stage amyloidosis study

Takeda Pharmaceutical Co. Ltd. will discontinue a late-stage study testing the company’s experimental treatment for amyloidosis, which did not meet the first of two main goals.

Read More »

Rare Cancer Treatments and the Power of Checkpoint Inhibitors Among Hot Topics at ASCO

With the books closed on another ASCO meeting, it’s clear to see that checkpoint inhibitors keep showing a promise.

Read More »

Melanoma can occur on skin that does not get much sun

Spending time in the sun without protection increases the risk of melanoma, but the potentially deadly skin cancer can occur even on sites with minimal sun exposure, doctors warn.

Read More »

Camurus Announces Publication of Phase 3 Study Results Showing Long-term Safety, Efficacy and High Rates of Patient Satisfaction With Buvidal

Camurus announced that the leading drug dependence journal Addiction published full results from a 48-week, open-label, global Phase 3 study of weekly and monthly Buvidal (prolonged-release buprenorphine), the first long-acting injection medicine to be approved for the treatment of opioid dependence in the EU and Australia.

Read More »

Without older subjects, cancer drug trials rely on atypical patients

Cancer drug study patients tend to be younger than most people with the disease in the general population.

Read More »

Weekend Highlights from 2019 ASCO Annual Meeting

There was a flurry of activity during the first few days of the American Society of Clinical Oncology, with multiple presentations made showing the benefits of various oncology treatments.

Read More »

Amgen drug shows high response rate in small lung and colon cancer trial

An experimental Amgen Inc. drug that targets a specific genetic mutation significantly reduced tumor size in half of evaluated patients with advanced lung cancer in a small, early-stage trial, sending the U.S. biotechnology company’s share up nearly 6 percent.

Read More »

Lynparza stalls pancreatic cancer in patients with BRCA mutations: study

AstraZeneca and Merck & Co.’s Lynparza helped patients with advanced pancreatic cancer who carry BRCA gene mutations go nearly twice as long without their disease worsening than those who received a placebo, according to data from a late-stage clinical trial.

Read More »

ADHD may be more common among elite athletes

ADHD (attention-deficit/hyperactivity disorder) may be more common in elite athletes, a new research review suggests.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom